Table 1

Patient demographics and baseline disease characteristics (as-treated population)

Central ALK-testing subgroup (n=908)Local ALK-testing subgroup
(n=158)
All patients
(n=1066)
Sex
 Male393 (43)72 (46)465 (44)
 Female515 (57)86 (54)601 (56)
Age (years), n (%)
 <65 years777 (86)117 (74)894 (84)
 ≥65 years131 (14)41 (26)172 (16)
 Median (range)52.0 (19–84)53.0 (21–84)52.0 (19–84)
Race n (%)
 White434 (48)98 (62)532 (50)
 Black16 (2)4 (3)20 (2)
 Asian442 (49)53 (34)495 (46)
  Japanese67 (7)14 (9)81 (8)
  Korean138 (15)6 (4)144 (14)
  Chinese224 (25)28 (18)252 (24)
  Other Asian13 (1)5 (3)18 (2)
 Other16 (2)3 (2)19 (2)
Smoking classification, n (%)
 Never612 (67)90 (57)702 (66)
 Former259 (29)62 (39)321 (30)
 Current37 (4)6 (4)43 (4)
Duration since histopathological diagnosis (years)
 Mean (range)2.1 (0.0–13.7)*1.8 (0.1–9.5)2.1 (0.0–13.7)
Extent of disease, n (%)
 Locally advanced77 (9)9 (6)86 (8)
 Metastatic831 (92)149 (94)980 (92)
Histological classification, n (%)
 Adenocarcinoma859 (95)147 (93)1006 (94)
 Squamous-cell carcinoma22 (2)4 (3)26 (2)
 Large-cell carcinoma7 (<1)2 (1)9 (<1)
 Other†20 (2)5 (3)25 (2)
ECOG performance status, n (%)
 0214 (24)38 (24)252 (24)
 1541 (60)94 (60)635 (60)
 2125 (14)18 (11)143 (13)
 328 (3)8 (5)36 (3)
Number of prior therapies for metastatic disease
 02 (<1)02 (<1)
 1231 (25)67 (42)298 (28)
 2335 (37)49 (31)384 (36)
 ≥3340 (37)42 (27)382 (36)
  • Data are n (%) unless otherwise indicated.

  • *Disease duration was not specified for one patient.

  • Other classification includes adenosquamous carcinoma, sarcomatoid, mucoepidermoid, epidermoid, hepatoid carcinoma and other.

  • ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.